GALAD score: Validation of the combination of biomarkers in diagnosing hepatocellular carcinoma
Main Article Content
Keywords
Abstract
Objective: To evaluate the validation of GALAD score in diagnosis of hepatocellular carcinoma. Subject and method: A cross-sectional descriptive study was done on 64 newly diagnosed hepatocellular carcinoma patients and 64 patients with cirrhosis, chronic hepatitis B/C without HCC at Hanoi Medical University Hospital. Result: AFP, AFP-L3, and PIVKA II serum levels were significantly elevated in hepatocellular carcinoma compared with chronic liver diseases without HCC (p<0.01). Area under curve values were 0.758; 0.670; 0.794, respectively. Meanwhile the GALAD score showed an area under curve of 0.812 (95% CI: 0.735 - 0.888). GALAD score with optimal cut-off point was 1.66 leading to 60.9% sensitivity, 93.7% specificity. Conclusion: The GALAD score performance is significantly higher in detecting HCC than single three markers.